文献速递生殖医学

体外受精不孕女性每日4 mg与10 mg醋酸甲羟孕酮行孕激素促排卵的妊娠结局:一项随机对照试验

The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial.
PubMed 文献 · BJOG · 2017-01-01

一项随机平行对照试验纳入300例卵巢储备正常的不孕女性,比较每日4 mg与10 mg醋酸甲羟孕酮行孕激素促排卵的临床结局。两组获卵数、可移植胚胎数、临床妊娠率及活产率均相似,均未发生早发LH峰和卵巢过度刺激综合征。每日4 mg醋酸甲羟孕酮足以防止IVF/ICSI治疗中LH提前升高。

要点

  • 每日4 mg与10 mg醋酸甲羟孕酮促排卵的获卵数和可移植胚胎数相似。
  • 两组临床妊娠率和活产率无显著差异。
  • 两组均未出现早发LH峰和卵巢过度刺激综合征。

核心结论

  • 每日4 mg或10 mg醋酸甲羟孕酮行孕激素促排卵在获卵数和冻融胚胎移植后妊娠结局方面相当。
  • 每日4 mg醋酸甲羟孕酮足以预防IVF/ICSI治疗中LH提前升高。

研究设计与样本

  • 随机平行对照试验,在三级学术医疗中心开展。
  • 纳入300例卵巢储备正常的不孕女性,接受IVF/ICSI治疗。
  • 从周期第3天起同时使用人绝经期促性腺激素(hMG;每日225 iu)和醋酸甲羟孕酮(A组每日10 mg;B组每日4 mg)。
  • 优势卵泡成熟时使用人绒毛膜促性腺激素(hCG;1000 iu)和促性腺激素释放激素激动剂(GnRH激动剂;0.1 mg)共同触发排卵。
  • 两组均将可移植胚胎冷冻保存,择期行冻融胚胎移植(FET)。

主要发现

  • 获卵数A组9.8 ± 6.3 vs B组9.6 ± 5.9,P > 0.05。
  • 可移植胚胎数A组4.2 ± 2.6 vs B组3.7 ± 3.0,P > 0.05。
  • 临床妊娠率A组58.0% vs B组48.7%,P > 0.05。
  • 每名参与者活产率A组48.7% vs B组42.0%,P > 0.05。
  • 两组均未发生早发LH峰和卵巢过度刺激综合征(OHSS)。

临床怎么用

  • 每日4 mg醋酸甲羟孕酮足以预防IVF/ICSI治疗中LH提前升高。
  • 每日4 mg或10 mg醋酸甲羟孕酮促排卵的获卵数和妊娠结局相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the clinical outcome and endocrinological characteristics of progestin-primed ovarian stimulation (PPOS) using 4 versus 10 mg of medroxyprogesterone acetate (MPA) per day in infertile women with normal ovary reserve. DESIGN: A randomised parallel controlled trial. SETTING: Tertiary-care academic medical centre. PARTICIPANTS: A cohort of 300 infertile women undergoing in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) treatment. METHODS: Human menopausal gonadotropin (hMG; 225 iu per day) and MPA (group A, 10 mg per day; group B, 4 mg per day) were started simultaneously from cycle day 3 onwards. Ovulation was co-triggered by human chorionic gonadotropin (hCG; 1000 iu) and gonadotropin-releasing hormone agonist (GnRH agonist; 0.1 mg) when dominant follicles matured. Viable embryos were cryopreserved for later frozen embryo transfer (FET) in both groups. MAIN OUTCOME MEASURES: The primary outcome measure was the number of oocytes retrieved. Secondary outcomes included the incidence of a premature surge in luteinising hormone (LH), the number of viable embryos, and clinical pregnancy outcomes. RESULTS: The number of oocytes retrieved and viable embryos were similar between two groups (9.8 ± 6.3 versus 9.6 ± 5.9; 4.2 ± 2.6 versus 3.7 ± 3.0; P > 0.05). No significant difference was found in clinical pregnancy rate (58.0 versus 48.7%) and live birth rate per participant (48.7 versus 42.0%; P > 0.05). No premature LH surge and ovarian hyperstimulation syndrome (OHSS) occurred in either group. CONCLUSIONS: Progestin-primed ovarian stimulation (PPOS) using 4 or 10 mg of MPA per day was comparable in terms of the number of oocytes retrieved and pregnancy outcome after FET. The administration of 4 mg of MPA per day was sufficient to prevent an untimely LH rise in women undergoing IVF/ICSI treatment. TWEETABLE ABSTRACT: An RCT confirmed similar pregnancy outcome in P-primed ovarian stimulation with a daily dose of 4 or 10 mg MPA.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Dong J, Wang Y, Chai WR, et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG. 2017. PMID: 28276192. doi:10.1111/1471-0528.14622

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。